Microbiomes

Avalife Is Supporting the Brain Through the Stomach

Retrieved on: 
Tuesday, August 3, 2021
Branches of biology, Anatomy, Digestive system, Environmental microbiology, Firmicutes, Microbiomes, Organs anatomy), Brain, Gut–brain axis, Mental health

In all cases, though, the goal is simple: to support the body's overall balance and well-being including mental health through a strong digestive system.

Key Points: 
  • In all cases, though, the goal is simple: to support the body's overall balance and well-being including mental health through a strong digestive system.
  • A growing body of research has revealed how closely the brain and the gut work together a phenomenon known as the "gut-brain axis."
  • About Avalife: Avalife's parent company, Avacare Global, was founded by Dr. Vikram Naik in South Africa in 1997.
  • Avacare is the company's division that is focused on holistic solutions and targets natural and complementary medicine in pursuit of that end.

Ancilia Biosciences Awarded NSF Grant to Advance Platform Designed to Address Overlooked Obstacle to Success for Microbiome Therapeutics

Retrieved on: 
Tuesday, August 3, 2021
Microbiomes, Bacteriology, Environmental microbiology, Branches of biology, Bacteriophage, Biology, Gut microbiota, Organisms, Articles, Microbiome

We founded Ancilia to overcome what our researchers believe is a significant obstacle to this successthe failure to address the presence of phages that infect commensal microbiome bacteria.

Key Points: 
  • We founded Ancilia to overcome what our researchers believe is a significant obstacle to this successthe failure to address the presence of phages that infect commensal microbiome bacteria.
  • There is evidence that phages are associated with disease and that they may also compromise the efficacy of LBPs.
  • We are delighted that the NSF sees potential in our technology and is supporting further development of our platform."
  • Ancilia Biosciences ( www.anciliabio.com) is developing virus-resistant live bacterial biotherapeutics (LBPs) to alter the gut microbiome and treat disease.

The Biocodex Microbiota Foundation calls for Canadian proposals to study the microbiome’s role in health and diseases

Retrieved on: 
Wednesday, July 28, 2021
Microbiology, Microbiomes, Bacteriology, Branches of biology, Dutch inventions, Bacteria, Environmental microbiology, Microbiota, Microbiome, Human microbiome

The Biocodex Microbiota Foundations annual call for projects is part of a multi-year research initiative to further the understanding of the human microbiome.

Key Points: 
  • The Biocodex Microbiota Foundations annual call for projects is part of a multi-year research initiative to further the understanding of the human microbiome.
  • Biocodex currently holds 20 subsidiaries (including Biocodex Canada Inc. based in Montral Quebec) and multiple long-term partnerships spanning more than 124 countries.
  • The Biocodex Microbiota Foundation is a non-profit, general interest organization that supports research into microbiota and their interaction with various pathologies.
  • Projects investigating the implication of microbiota in human health are selected annually by committees of independent international scientists.

CN Bio licenses human gut microbiome modelling tool from MIT and Northeastern University

Retrieved on: 
Tuesday, July 27, 2021
Software, Biotechnology, Pharmaceutical, Health, Technology, University, Genetics, Education, Microbiology, Microbiomes, Bacteriology, Environmental microbiology, Branches of biology, Medical specialties, Microbiome, Human microbiome, Gut microbiota, Human Microbiome Project

CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.

Key Points: 
  • CN Bio, a leading Organ-on-a-chip Company (OOC) that designs and manufactures single- and multi-organ microphysiological systems (MPS), today announced it has secured the licensing rights to a novel tool for modelling the gut microbiome, GuMI, from Massachusetts Institute of Technology (MIT) and Northeastern University.
  • The ability to study the human microbiome and its effects on human health is an area of great research interest and a pivotal application for OOC technology.
  • Modelling the human microbiome in the laboratory is challenging, especially since many of its several thousand strains of bacteria cannot grow or survive when exposed to oxygen.
  • Dr David Hughes, CEO, CN Bio, commented: We are rapidly coming to appreciate the important role the microbiome plays in human health and disease.

DSM acquires next-generation eubiotics platform start-up

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Natural sciences, Physical sciences, Microbiomes, Biomin, Biotechnology, Carbohydrate chemistry, Bacteriology, DSM, Gut microbiota, Shōjo Tsubaki, Midori

DSM already owns 38.5% of the shares of Midori and has today acquired the remaining 61.5% for a consideration of US$63m.

Key Points: 
  • DSM already owns 38.5% of the shares of Midori and has today acquired the remaining 61.5% for a consideration of US$63m.
  • Boston Massachusetts-based Midori has developed a technology platform that identifies glycans derived from natural food sugars that can precisely modulate how the gut microbiome functions in animals.
  • Such eubiotics can reduce the environmental footprint of animal farming and support the accelerated replacement of antibiotics in animal feed.
  • Midori's platform is highly synergetic with DSM's bioscience capability and current eubiotics portfolio, which was further strengthened through the acquisition of Biomin (as part of the Erber Group) .

Virtual Lecture on First-of-its-Kind Research Exploring the Influence of Pet Ownership on the Gut Microbiome

Retrieved on: 
Thursday, July 22, 2021
Branches of biology, Microbiomes, Microbiology, Bacteriology, Medical specialties, Environmental microbiology, Digestive system, Gut microbiota, Microbiota, Human microbiome, Cardiovascular disease, Microbiome

WASHINGTON, July 22, 2021 /PRNewswire-PRWeb/ --The Human Animal Bond Research Institute (HABRI) and IDEXX today hosted the fifth virtual lecture in the successful Human-Animal Bond Lecture Series, focused on the rationale and anticipated results of new, first-of-its-kind research exploring the influence of pet ownership on the gut microbiome and cardiovascular disease (CVD) risk in older adults.

Key Points: 
  • WASHINGTON, July 22, 2021 /PRNewswire-PRWeb/ --The Human Animal Bond Research Institute (HABRI) and IDEXX today hosted the fifth virtual lecture in the successful Human-Animal Bond Lecture Series, focused on the rationale and anticipated results of new, first-of-its-kind research exploring the influence of pet ownership on the gut microbiome and cardiovascular disease (CVD) risk in older adults.
  • This lecture, titled "The association of pet ownership, the gut microbiome, and cardiovascular disease risk among older adults", features Dr. Katharine Watson, MA, BVMS, discussing her active HABRI-funded study, "The influence of pet ownership on gut microbiota composition and cardiovascular disease risk among 50 to 85-year old United States adults".
  • The human microbiota is made up of trillions of cells, with the biggest populations residing in the gut.
  • Much of the science on the physical health benefits of pets involve the association between pet ownership and physical activity.

Vedanta Biosciences Completes $68 Million Series D Financing

Retrieved on: 
Wednesday, July 21, 2021
Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Microbiomes, Microbiology, Branches of biology, Bacteriology, Dutch inventions, Environmental microbiology, Microbiome, Microscopy, Human microbiome, Magnetar Capital

Vedanta Biosciences , Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced the closing of a $68 million Series D financing and provided a pipeline update.

Key Points: 
  • Vedanta Biosciences , Inc., a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced the closing of a $68 million Series D financing and provided a pipeline update.
  • The Series D financing was led by affiliates of Magnetar Capital.
  • We are delighted to welcome the new investors in our Series D round and are grateful to our existing shareholders and partners for their continued support, said Bernat Olle, Ph.D., Co-founder and Chief Executive Officer of Vedanta Biosciences.
  • Vedanta Biosciences is developing a potential new category of oral therapies based on rationally defined consortia of bacteria derived from the human microbiome.

MaaT Pharma Awarded France Relance Government Grant to Accelerate Development in Immuno-Oncology and Support Manufacturing of Next Generation Microbiome Therapies

Retrieved on: 
Tuesday, July 20, 2021
Oncology, Health, Research, Pharmaceutical, Science, Biotechnology, Microbiome, Microbiomes, Environmental microbiology, Bacteriology

Initiated during the Summer of 2020, Plan France Relance was established to make strategic investments in critical sectors of French industry, including Health.

Key Points: 
  • Initiated during the Summer of 2020, Plan France Relance was established to make strategic investments in critical sectors of French industry, including Health.
  • The France Relance program will support the development of our unique and innovative industrial processes that leverage all the functional diversity of the microbiome to deliver better outcomes in cancer treatment.
  • Ultimately, MaaT Pharmas manufacturing platform may be used to deliver a large range of microbiome ecosystem therapies in various indications.
  • MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to spearhead microbiome treatment integration into clinical practice.

Evvy Introduces the First At-Home Vaginal Microbiome Test Leveraging Metagenomic Sequencing

Retrieved on: 
Wednesday, July 14, 2021
Branches of biology, Microbiology, Biology, Bacteriology, Microbiomes, Environmental microbiology, Gynaecology, Vagina, Metagenomics, Microbiome, Draft:Juno Bio

Evvy's at-home vaginal microbiome test leverages metagenomic sequencing to help anyone with a vagina understand what's up down there, why it matters, and what they can do about it.

Key Points: 
  • Evvy's at-home vaginal microbiome test leverages metagenomic sequencing to help anyone with a vagina understand what's up down there, why it matters, and what they can do about it.
  • Evvy's Vaginal Health Test finally gives women access to this data, enabling them to take control of their preventative health.
  • "Evvy is breaking boundaries to advance women's health with more affordable and comprehensive testing starting with its vaginal microbiome metagenomics test," says Margo Georgiadis.
  • The Evvy Vaginal Health Test is available in all 50 states and performed as a simple, at-home swab.

Biocodex Microbiota Foundation Announces Open Call for 2021 US Research Grant Applications

Retrieved on: 
Friday, July 9, 2021
Microbiology, Microbiomes, Bacteriology, Branches of biology, Dutch inventions, Bacteria, Microbiota, Human microbiome

BEDMINSTER, N.J., July 9, 2021 /PRNewswire-PRWeb/ --The Biocodex Microbiota Foundation , an organization founded by Biocodex and committed to inspiring scientific projects that investigate the implication of the microbiota in human health, has announced its 2021 open call for applications for its annual US research grant.

Key Points: 
  • BEDMINSTER, N.J., July 9, 2021 /PRNewswire-PRWeb/ --The Biocodex Microbiota Foundation , an organization founded by Biocodex and committed to inspiring scientific projects that investigate the implication of the microbiota in human health, has announced its 2021 open call for applications for its annual US research grant.
  • The Biocodex Microbiota Foundation's annual call for grant applications is part of a multi-year research initiative to understand the interaction between microbiota and different pathologies.
  • To learn more information about Biocodex Microbiota Foundation and the 2021 US grant program click here.
  • The Biocodex Microbiota Foundation supports both foundational and applied research, and projects are selected annually by a committee of independent scientists.